Researchers found that inhibiting CPE expression in pancreatic tumor cells can suppress cell growth and metastasis by regulating pathways such as p53, Wnt signaling, and downstream target nuclear factor κB (NF-κB), thereby increasing the drug sensitivity of pancreatic cancer patients to cisplatin (27, 28). Here, NFKB1 is linked to familial pancreatic carcinoma.